Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
1.680
-0.280 (-14.29%)
At close: Jun 26, 2026, 4:00 PM EDT
1.780
+0.100 (5.95%)
After-hours: Jun 26, 2026, 7:52 PM EDT
Actuate Therapeutics Employees
Actuate Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 2 or 20.00% compared to the previous year.
Employees
12
Change (1Y)
2
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,794,715
Market Cap
40.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12 | 2 | 20.00% |
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| INmune Bio | 21 |
| ABVC BioPharma | 19 |
| RenovoRx | 17 |
| Apollomics | 14 |
| Nutriband | 13 |
| Genenta Science | 9 |
| Hyperion DeFi | 9 |
| KALA BIO | 6 |
ACTU News
- 18 days ago - Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma - GlobeNewsWire
- 26 days ago - Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital - TheFly
- 6 weeks ago - Actuate Therapeutics Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Actuate Therapeutics receives FDA clearance for oral elraglusib study - TheFly
- 6 weeks ago - Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program - GlobeNewsWire
- 7 weeks ago - Analysts see 200%+ upside in these 3 high-risk stocks: here's why? - Invezz
- 7 weeks ago - Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors - GlobeNewsWire